S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Aquestive Therapeutics (AQST) Earnings Date, Estimates & Call Transcripts

$4.50
+0.58 (+14.80%)
(As of 04/18/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 7Estimated
Actual EPS
(Mar. 5)
-$0.12 Missed By -$0.04
Consensus EPS
(Mar. 5)
-$0.08
Skip Charts & View Estimated and Actual Earnings Data

AQST Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AQST Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Aquestive Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242($0.09)($0.04)($0.07) 
Q2 20242($0.08)($0.08)($0.08) 
Q3 20242($0.07)($0.05)($0.06) 
Q4 20242($0.08)($0.04)($0.06) 
FY 20248($0.32)($0.21)($0.27) 
Q1 20251($0.07)($0.07)($0.07) 
Q2 20251($0.08)($0.08)($0.08) 
Q3 20251($0.08)($0.08)($0.08) 
Q4 20251($0.08)($0.08)($0.08) 
FY 20254($0.31)($0.31) ($0.31)

AQST Earnings Date and Information

Aquestive Therapeutics last announced its earnings data on March 5th, 2024. The reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.04. The business earned $13.21 million during the quarter, compared to analyst estimates of $11.79 million. Aquestive Therapeutics has generated ($0.14) earnings per share over the last year (($0.14) diluted earnings per share). Earnings for Aquestive Therapeutics are expected to grow in the coming year, from ($0.36) to ($0.32) per share. Aquestive Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 7th, 2024 based off prior year's report dates.

Aquestive Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/7/2024
Estimated)
------- 
3/5/2024Q4 2023($0.08)($0.12)($0.04)($0.12)$11.79 million$13.21 million
11/6/2023Q3 2023($0.11)($0.03)+$0.08($0.03)$11.33 million$13.00 million
8/7/2023Q2 2023($0.11)($0.10)+$0.01($0.10)$10.76 million$13.24 million
5/2/2023Q1 2023($0.10)$0.11+$0.21$0.11$10.17 million$11.13 million
3/8/2023Q4 2022($0.21)($0.23)($0.02)($0.23)$9.93 million$10.68 million    
11/1/2022Q3 2022($0.30)($0.23)+$0.07($0.23)$10.68 million$11.46 million
8/2/2022Q2 2022($0.41)($0.36)+$0.05($0.36)$10.02 million$13.27 million    
5/3/2022Q1 2022($0.45)($0.32)+$0.13($0.32)$9.80 million$12.27 million    
3/8/2022Q4 2021($0.37)($0.38)($0.01)($0.04)$9.81 million$11.08 million    
11/2/2021Q3 2021($0.45)($0.37)+$0.08($0.37)$12.03 million$13.29 million    
8/2/2021Q2 2021($0.44)($0.33)+$0.11($0.33)$10.63 million$15.35 million    
5/3/2021Q1 2021($0.43)($0.41)+$0.02($0.41)$9.15 million$11.12 million  

Aquestive Therapeutics Earnings - Frequently Asked Questions

When is Aquestive Therapeutics's earnings date?

Aquestive Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 7th, 2024 based off last year's report dates. Learn more on AQST's earnings history.

Did Aquestive Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Aquestive Therapeutics (NASDAQ:AQST) missed the analysts' consensus estimate of ($0.08) by $0.04 with a reported earnings per share (EPS) of ($0.12). Learn more on analysts' earnings estimate vs. AQST's actual earnings.

How much revenue does Aquestive Therapeutics generate each year?

Aquestive Therapeutics (NASDAQ:AQST) has a recorded annual revenue of $50.58 million.

How much profit does Aquestive Therapeutics generate each year?

Aquestive Therapeutics (NASDAQ:AQST) has a recorded net income of -$7.87 million. AQST has generated -$0.14 earnings per share over the last four quarters.

What is Aquestive Therapeutics's EPS forecast for next year?

Aquestive Therapeutics's earnings are expected to grow from ($0.36) per share to ($0.32) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:AQST) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners